DYNLL1 and hepatocellular carcinoma: For instance, DYNLL1 alternative splicing expression, which is significantly decreased in EGCG+HC treated glioma cells, is reported to be upregulated in gastric cancer high-risk group patients and hepatocellular cancer (Berkel and Cacan, 2020) (Li et al., 2021).